

carrier is selected from the group consisting of liposomes, cationic polymers, micelles and a combination thereof.

B<sup>1</sup>  
22. (Amended) The method of claim 21, wherein the RNA and carrier are administered via intravenous injection.

B<sup>2</sup>  
26. (Amended) A method for providing anti-angiogenic therapy to a subject in need thereof, which comprises administering by injection to the subject RNA encoding at least one anti-angiogenic protein or peptide in a carrier whereby the RNA is expressed and angiogenic growth is inhibited, wherein the carrier is selected from the group consisting of liposomes, cationic polymers, micelles and a combination thereof.

B<sup>3</sup>  
28. (Amended) The method of claim 26, wherein the injection is made into a tumor in the subject.

Please add the following new claims:

~~36.~~ A method for inhibiting tumor growth in a subject bearing a tumor, which comprises administering to the subject nucleic acid encoding at least one anti-angiogenic protein or peptide in a carrier whereby the nucleic acid is expressed and tumor growth is inhibited, wherein the carrier is selected from the group consisting of liposomes, cationic polymers, micelles and a combination thereof.

B<sup>4</sup>  
37. (New) The method of claim 36, wherein the nucleic acid and carrier are administered via intravenous injection.

38. (New) The method of claim 36, wherein the carrier is a liposomal carrier.

39. (New) The method of claim 36, wherein the carrier is a cationic polymer carrier.

40. (New) The method of claim 36, wherein the carrier is a micelle carrier.